Transgene S.A. has reported positive randomized Phase I data for TG4050, its individualized neoantigen therapeutic cancer vaccine, demonstrating a 100% disease-free survival rate after two years of follow-up in patients with operable Head and Neck Squamous Cell Carcinoma (HNSCC). This efficacy signal, initially presented as a rapid oral presentation at ASCO in June 2025, underscores the potential of virus-based immunotherapies leveraging the myvac platform to stimulate anti-tumor immune responses. The company is now advancing toward Phase II randomization completion by late 2025, with financial runway secured through December 2026.
Clinical Efficacy Signals
The Phase I trial results for TG4050 in operable HNSCC highlight a robust clinical outcome, with patients achieving 100% disease-free survival over a two-year observation period. These findings were disseminated via a rapid oral presentation at the American Society of Clinical Oncology (ASCO) conference in June 2025, providing early validation of the vaccine's ability to induce durable responses in this specific patient population.
Development Timeline
Transgene is currently conducting the Phase II part of the trial for TG4050 in operable HNSCC, having completed patient screening. The company anticipates completing randomization in the fourth quarter of 2025. Subsequent milestones include the reporting of additional immunological data at a scientific conference in Q4 2025, with first immunogenicity data expected in the second half of 2026 and efficacy data projected for Q4 2027.
What to Watch
Investors and scientists should monitor the completion of Phase II randomization in Q4 2025 and the subsequent release of immunogenicity data in H2 2026. Additionally, Transgene is preparing a new Phase I trial in an additional indication, which will expand the scope of TG4050's clinical evaluation beyond HNSCC. The company’s financial stability through December 2026 provides a critical window for these pivotal data points to influence future valuation and partnership opportunities.
Sources
- Source article
- ImmunoNX: a robust bioinformatics workflow to support personal… — 2025-12-09
- Epitope analysis for influenza vaccine design — 2004-08-23
- Vaccine skepticism detection by network embedding — 2021-10-20
- pVACtools v6: A comprehensive suite for neoantigen prediction,… — 2026-06-25
- pVACview: an interactive visualization tool for efficient neoa… — 2024-06-11
- The impact of Covid-19 vaccination in Aotearoa New Zealand: a … — 2024-01-18
- The illicit trade of COVID-19 vaccines on the dark web — 2021-02-10
- Vaccination with Leishmania mexicana LPG induces PD-1 in CD8+ … — 2019-04-29